November 27, 2018 8:17am
Good news, bad press or the lack of makes markets melt just as Icarus had wings of feathers and wax
Out and about: Are the CRISPRS: CRSP (close +$0.82), EDIT (close +$0.73) and NTLA (-$0.02) about to feel more downside pressures over news of a Chinese scientist who used a powerful gene-editing technique to change the embryonic DNA of twins drew fire from ethicists and doctors in Massachusetts and from a professor at MIT who helped invent the tool.
Pre-open indications: 5 SELLs
I post about “indication intelligence” devoting my time to collection and analysis of information to assist investors in the perception of sector vulnerabilities and strengths – it’s more than opinion, the facts and truth need to be recognized!
A trusted source of factual reporting of preludes and aftermaths!
There’s a difference between trust and conviction. Trust is something you can rely on, beyond certainty. Conviction doesn't demand that you, or anyone else, play by the rules. After gains, there’s pain; followed by advances, declines and other progressions or was it regressions?
U.S. stock index futures are headed south …
Dow futures are DOWN -0.39% (-96 points) and NASDAQ futures are DOWN -0.61% (-41 points)
U.S. stock index futures fell ahead of Tuesday's open amid renewed concerns over U.S.-China trade relations;
European markets trade lower amid fresh trade concerns;
Asian markets traded higher as investors wait for Trump and Xi's meeting;
Data docket: the latest S&P Corelogic Case-Shiller home price index is slated to come out at 9 a.m. ET, followed by consumer confidence figures at 10 a.m. ET.
- The iShares Nasdaq Biotechnology (IBB) is NOT indicating
- The SPDR S&P Biotech ETF (XBI) is NOT indicating
- The Health Care Select Sector SPDR ETF (XLV) is NOT indicating
- The iShares Russell 2000 (IWM) is indicating a NEGATIVE -0.49% DOWNSIDE
The moves in U.S. futures come after Monday’s session finished sharply higher, with the Dow closing more than 350 points higher. Looking overseas, markets appear somewhat cautious with Asia closing mostly in the black; with Europe trading slightly lower <CNBC>.
I am RESUMING my cautious approach to ANY new purchases; I perceive a run on the upside!
Last night’s closing bell remarks, “sector stays up on what as the NASDAQ (+2%) and IBB (+1.7%) jump?
Monday night’s percentage (%) indicators:
- Review the range of the 25 upside from +0.48% (BLCM) to +8.09% (FATE) while the 18 downside ranged from -0.12% (NTLA) to -8.13% (AST -$0.10) with a 2 flat close (BSTG and CLBS).
- 5 out of the 25 upside had higher (than the 3 month average) volume
- 7 out of 18 downside experienced greater volume (than the 3 month average).
In 18 sessions in November – there were 1 holiday, 8 positive closes, 1 neutral and 8 negative closes
- In 23 sessions in October – there were 17 negative closes and 6 positive sessions;
- In 19 sessions in September – there were 10 negative closes and 9 positive sessions;
- In 21 August sessions – 6 had negative and 15 had positive closes
Companies in my headlights – It’s your decision; I provide an idea and context:
bluebird bio (BLUE) closed up +$6.10 to $128.24 and has a negative -$1.28 or -1% aftermarket indication – SELL;
Alnylam Pharmaceuticals (ALNY) closed up +$5.01 to $78.35 and has a negative -$0.78 or -0.99% aftermarket indication – SELL;
Are CRISPR Therapeutics (CRSP close +$0.82), Editas Medicine (EDIT close +$0.73) and Intellia Therapeutics (NTLA (-$0.02) going to be hit HARD by the news cycle when a Chinese scientist who used a powerful gene-editing technique to change the embryonic DNA of twins drew fire from ethicists and doctors in Massachusetts and from a professor at MIT who helped invent the tool - SELL
Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.
Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors. All investments are subject to risks. Investors should consider investment objectives.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.